Amyris Inc (NASDAQ:AMRS) Director L John Doerr acquired 10,505,652 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $2.87 per share, with a total value of $30,151,221.24. Following the completion of the purchase, the director now directly owns 7,798 shares of the company’s stock, valued at approximately $22,380.26. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
AMRS traded up $0.30 on Tuesday, hitting $2.86. 3,471,400 shares of the company were exchanged, compared to its average volume of 1,708,070. Amyris Inc has a twelve month low of $1.87 and a twelve month high of $6.06. The company has a market cap of $308.06 million, a price-to-earnings ratio of -0.92 and a beta of 0.84. The firm has a 50-day moving average price of $3.02 and a two-hundred day moving average price of $3.59.
Amyris (NASDAQ:AMRS) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.51) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.02. The company had revenue of $34.95 million for the quarter, compared to analyst estimates of $21.60 million. Research analysts forecast that Amyris Inc will post -2.36 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMRS. Traynor Capital Management Inc. lifted its holdings in Amyris by 33.3% during the 3rd quarter. Traynor Capital Management Inc. now owns 14,000 shares of the biotechnology company’s stock worth $66,000 after buying an additional 3,500 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Amyris by 8.8% in the 3rd quarter. Rhumbline Advisers now owns 54,258 shares of the biotechnology company’s stock valued at $258,000 after purchasing an additional 4,379 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of Amyris by 2.6% in the 3rd quarter. Rice Hall James & Associates LLC now owns 192,946 shares of the biotechnology company’s stock valued at $918,000 after purchasing an additional 4,915 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Amyris in the 3rd quarter valued at about $48,000. Finally, California Public Employees Retirement System purchased a new stake in shares of Amyris in the 3rd quarter valued at about $58,000. 28.65% of the stock is owned by hedge funds and other institutional investors.
AMRS has been the subject of a number of research reports. Zacks Investment Research cut Amyris from a “buy” rating to a “hold” rating in a research note on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Amyris in a research note on Friday, October 11th. Oppenheimer reissued a “buy” rating on shares of Amyris in a research note on Monday. Finally, BidaskClub cut Amyris from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 30th.
About Amyris
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
Featured Story: Does a trade war provide a risk to the global economy?
-